All In Biotech

Drug Trial Radar · NCT06763926

Intranasal Nafarelin For Triggering Oocyte Maturation

Intranasal Nafarelin Compared to Subcutaneous Triptorelin for Triggering Final Oocyte Maturation in Ovarian Stimulation: a Non-inferiority Randomised Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Jan 15, 2028

Study completion Jan 15, 2028

Sponsor

Lead sponsor
Fundacion DexeusAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.

Conditions

  • Fertility Preservation

Interventions

  • Subcutaneous TriptorelinDrug

    Women undergoing fertility preservation will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit.. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion. Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms. n the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection.

  • Intranasal nafarelinDrug

    Women undergoing fertility preservation will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion. Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of MII (metaphase 2) oocyte retrievedTime frame: Until study completion - average of 10-20 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus

    Barcelona, Spain · Recruiting

  • Dexeus Mujer Tarragona

    Tarragona, Spain · Not yet recruiting

  • Dexeus Mujer Sabadell

    Sabadell, Barcelona, Spain · Not yet recruiting

  • Dexeus Mujer Sant Cugat

    Sant Cugat del Vallès, Barcelona, Spain · Not yet recruiting

  • Dexeus Mujer Reus

    Reus, Tarragona, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.